DAFTAR PUSTAKA

Abidi, S., Achar, J., Neino, M. M. A., Bang, D., Benedetti, A., Brode, S., ... & Khan, F. A. (2020). Standardized shorter regimens versus individualized longer regimens for rifampin-or multidrug-resistant tuberculosis. European Respiratory Journal, 55(3).

Adiwinata, R., Rasidi, J., Marpaung, M., Timur, K., & Timur, K. (2018). Profil klinis dan evaluasi pengobatan pasien rifampicin-resistant dan multidrug-resistant tuberculosis di RSUD dr. *Kanujoso Djatiwibowo Balikpapan. J Respir Indo*, *38*(3), 135-142.

Afsar Khan Afridi, M. D. (2016). Occurrence, Management, and Risk Factors for Adverse Drug Reactions in Multidrug Resistant Tuberculosis Patients.

Agyeman, A. A., & Ofori-Asenso, R. (2017). Tuberculosis—an overview. *Journal of Public Health and Emergency*, *1*(7), 1-11.

Ahuja, S. D., Ashkin, D., Avendano, M., Banerjee, R., Bauer, M., Bayona, J. N., ... & Yim, J. J. (2012). Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients.

Anisah, A., Sumekar, D. W., & Budiarti, E. (2021). Demografi dan Komorbid dengan Kejadian Tuberkulosis Resisten Obat (TB RO). *Jurnal Ilmiah Kesehatan Sandi Husada*, *10*(2), 568-574.

Atif, M., Ahmed, W., Nouman Iqbal, M., Ahmad, N., Ahmad, W., Malik, I., & Al-Worafi, Y. M. (2022). Frequency and factors associated with adverse events among multi-drug resistant tuberculosis patients in Pakistan: a retrospective study. *Frontiers in Medicine*, *8*, 790718.

Bernabe-Ortiz, A., Carcamo, C. P., Sanchez, J. F., & Rios, J. (2011). Weight variation over time and its association with tuberculosis treatment outcome: a longitudinal analysis. *PloS one*, *6*(4), e18474.

Chakaya, J., Khan, M., Ntoumi, F., Aklillu, E., Fatima, R., Mwaba, P., ... & Zumla, A. (2021). Global Tuberculosis Report 2020–Reflections on the Global TB burden, treatment and prevention efforts. *International journal of infectious diseases*, *113*, S7-S12.

Conradie, F., Diacon, A. H., Ngubane, N., Howell, P., Everitt, D., Crook, A. M., ... & Spigelman, M. (2020). Treatment of highly drug-resistant pulmonary tuberculosis. *New England Journal of Medicine*, *382*(10), 893-902.

Dewi, A. P. (2020). Prevalence and characteristic of drug-resistant tuberculosis patients in South Halmahera District, eastern Indonesia.

Diacon, A. H., Pym, A., Grobusch, M. P., de Los Rios, J. M., Gotuzzo, E., Vasilyeva, I., ... & Dannemann, B. (2014). Multidrug-resistant tuberculosis and culture conversion with bedaquiline. *New England Journal of Medicine*, *371*(8), 723-732.

Dinas Kesehatan Kabupaten Banyumas. (2023). *Profil Kesehatan Kabupaten Banyumas Tahun 2022*. Banyumas: Dinas Kesehatan Kabupaten Banyumas

Dinas Kesehatan Provinsi Jawa Tengah. (2022). *Profil Kesehatan Jawa Tengah Tahun 2021*. Semarang: Dinas Kesehatan Provinsi Jawa Tengah.

Ducati, R. G., Ruffino-Netto, A., Basso, L. A., & Santos, D. S. (2006). The resumption of consumption: a review on tuberculosis. *Memórias do Instituto Oswaldo Cruz*, *101*, 697-714.

Falzon, D., Jaramillo, E., Schünemann, H. J., Arentz, M., Bauer, M., Bayona, J., ... & Zignol, M. (2011). WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update.

Falzon, D., Schünemann, H. J., Harausz, E., González-Angulo, L., Lienhardt, C., Jaramillo, E., & Weyer, K. (2017). World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update. The European respiratory journal, 49(3), 1602308.

Fu, L., Weng, T., Sun, F., Zhang, P., Li, H., Li, Y., ... & Deng, G. (2021). Insignificant difference in culture conversion between bedaquiline-containing and bedaquiline-free all-oral short regimens for multidrug-resistant tuberculosis. *International Journal of Infectious Diseases*, *111*, 138-147.

Furin, J., Cox, H., & Pai, M. (2019). Tuberculosis. *Lancet (London, England)*, *393*(10181), 1642–1656.

Gilpin, C., Korobitsyn, A., & Weyer, K. (2016). Current tools available for the diagnosis of drug-resistant tuberculosis. *Therapeutic advances in infectious disease*, *3*(6), 145-151.

Granich, R. M., Oh, P., Lewis, B., Porco, T. C., & Flood, J. (2005). Multidrug resistance among persons with tuberculosis in California, 1994-2003. *Jama*, *293*(22), 2732-2739.

Grosset, J. H., Tyagi, S., Almeida, D. V., Converse, P. J., Li, S. Y., Ammerman, N. C., ... & Trébucq, A. (2013). Assessment of clofazimine activity in a second-line regimen for tuberculosis in mice. American journal of respiratory and critical care medicine, 188(5), 608-612.

Heriqbaldi, A. Z., Setiabudi, R. J., & Meliana, R. Y. (2022). First-Line Anti-Tuberculosis Drug Resistance Pattern. *J Respirasi*, *8*(1), 1.

Hirpa, S., Medhin, G., Girma, B., Melese, M., Mekonen, A., Suarez, P., & Ameni, G. (2013). Determinants of multidrug-resistant tuberculosis in patients who underwent first-line treatment in Addis Ababa: a case control study. *BMC public health*, *13*, 1-9.

Hughes, G., Bern, H., Chiang, C. Y., Goodall, R. L., Nunn, A. J., Rusen, I. D., & Meredith, S. K. (2022). QT prolongation in the STREAM Stage 1 Trial. *The International Journal of Tuberculosis and Lung Disease*, *26*(4), 334-340.

Ifayani, O., Puspitasari, I. M., Insani, W. N., & Pradipta, I. S. (2023). Efek Samping Obat Pada Pengobatan Tuberkulosis Resisten Obat Ganda. *Majalah Farmasi dan Farmakologi*, 27(1), 10-14.

Inayah, S., & Wahyono, B. (2019). Penanggulangan Tuberkulosis Paru dengan Strategi DOTS. *HIGEIA (Journal of Public Health Research and Development)*, *3*(2), 223-233.

Ismaya, N. A., Andriati, R., Aripin, A., Ratnaningtyas, T. O., & Tafdhiila, F. (2022). Rasionalitas Obat Anti Tuberkulosis Pada Pasien Tb Paru Rawat

Inap Di Rumah Sakit Umum Kota Tangerang Selatan. *Edu Masda Journal*, *5*(2), 125-135.

Kementerian Kesehatan Republik Indonesia. (2011). *Modul Penggunaan Obat Rasional*. Jakarta: Kementerian Kesehatan Republik Indonesia.

Kementerian Kesehatan Republik Indonesia. (2020). Pedoman Nasional Pelayanan Kedokteran: Tatalaksana Tuberkulosis. *Jakarta: Kementerian Kesehatan Republik Indonesia*.

Kementerian Kesehatan Republik Indonesia. (2020). Petunjuk Teknis Penatalaksanaan Tuberculosis Resisten Obat Di Indonesia.*Jakarta: Kementerian Kesehatan Republik Indonesia*.

Kementerian Kesehatan Republik Indonesia. (2023). *Laporan Program Penanggulangan Tuberkulosis Tahun 2022*. Jakarta: Kementerian Kesehatan Republik Indonesia

Khawbung, J. L., Nath, D., & Chakraborty, S. (2021). Drug resistant Tuberculosis: A review. *Comparative immunology, microbiology and infectious diseases*, *74*, 101574.

Koch, A., Cox, H., & Mizrahi, V. (2018). Drug-resistant tuberculosis: challenges and opportunities for diagnosis and treatment. *Current Opinion in pharmacology*, *42*, 7-15.

Laili, F. N., Octavia, D. R., & Muhtaromah, M. (2023). Hubungan Kepatuhan Pengobatan TB-RO terhadap Outcome Terapi Pasien Tuberkulosis di Rumah Sakit Muhammadiyah Lamongan. *Jurnal Sains dan Kesehatan*, *5*(5), 659-665.

Lu, Z., Jiang, W., Zhang, J., Lynn, H. S., Chen, Y., Zhang, S., ... & Zhang, Z. (2019). Drug resistance and epidemiology characteristics of multidrug-resistant tuberculosis patients in 17 provinces of China. *PLoS One*, *14*(11), e0225361.

Merry, M. S., Rintiswati, N., & Wijayanti S, Y. (2016). Genotype And Resistance Patterns Of Anti Tuberculosis Treatment (Att) In Mycobacterium Tuberculosis Isolates From Tuberculosis Cases Which Not Taken Att. Berkala Ilmiah Kedokteran Duta Wacana, 1(2), 79. https://doi.org/10.21460/bikdw.v1i2.14

Mesfin, E. A., Beyene, D., Tesfaye, A., Admasu, A., Addise, D., Amare, M., ... & Tessema, B. (2018). Drug-resistance patterns of Mycobacterium tuberculosis strains and associated risk factors among multi drug-resistant tuberculosis suspected patients from Ethiopia. *PloS one*, *13*(6), e0197737.

Miotto, P., Cirillo, D. M., & Migliori, G. B. (2015). Drug Resistance inMycobacterium tuberculosis: Molecular Mechanisms Challenging Fluoroquinolones and Pyrazinamide Eff ectiveness. *Chest*, *147*(4), 1135-1143.

Munir, M. S., Nawas, A., & Soetoyo, D. K. (2008). Pengamatan pasien tuberkulosis paru dengan multidrug resistant (TB-MDR) di poliklinik paru RSUP Persahabatan. *Populasi*.

Nugrahaeni, D. K. (2015). Analisis penyebab resistensi obat anti tuberkulosis. *KEMAS: Jurnal Kesehatan Masyarakat*, *11*(1), 8-15.

Nuraini, N., Naziah, N., & Zainaro, M. A. (2018). Pengalaman Putus Obat pada Klien TB yang Mendapatkan Pengobatan Oat dengan Strategi Dots di RS Umum Kabupaten Tangerang Tahun 2016. *Jurnal JKFT*, *3*(2), 70-80.

Oehadian, A., Santoso, P., Menzies, D., & Ruslami, R. (2022). Concise clinical review of hematologic toxicity of linezolid in multidrug-resistant and extensively drug-resistant tuberculosis: role of mitochondria. Tuberculosis and Respiratory Diseases, 85(2), 111.

Pralambang, S. D., & Setiawan, S. (2021). Faktor risiko kejadian tuberkulosis di Indonesia. *Jurnal Biostatistik, Kependudukan, dan Informatika Kesehatan (BIKFOKES)*, *2*(1), 60-71.

Prasad, R., Singh, A., & Gupta, N. (2019). Adverse drug reactions in tuberculosis and management. indian journal of tuberculosis, 66(4), 520-532.

Putri, V. A., Yovi, I. Y., & Fauzia, D. (2015). *Profil pasien tuberculosis multidrug resistance (TB-MDR) di poliklinik TB-MDR RSUD Arifin Achmad Provinsi Riau periode April 2013-Juni 2014* (Doctoral dissertation, Riau University).

Qiao, J., Yang, L., Feng, J., Dai, X., Xu, F., & Xia, P. (2022). Analysis of efficacy and safety of linezolid-based chemotherapeutic regimens for patients with postoperative multidrug-resistant spinal tuberculosis. *International Journal of Infectious Diseases*, *118*, 264-269.

Qiyaam, N., Furqani, N., & Hartanti, D. J. (2020). Evaluasi Penggunaan Obat Antituberkulosis (OAT) Pada Pasien Tuberkulosis Paru di Puskesmas Kediri Lombok Barat Tahun 2018. *Lumbung Farmasi: Jurnal Ilmu Kefarmasian*, *1*(1), 1-7.

Rhines, A. S. (2013). The role of sex differences in the prevalence and transmission of tuberculosis. *Tuberculosis*, *93*(1), 104-107.

Rinawati, S. A. W. (2021). Indeks Massa Tubuh (IMT) Pasien Tuberkulosis Resisten Obat dan Kecenderungannya Terhadap Efek Samping Pengobatan. *Jurnal Teknologi Kesehatan (Journal of Health Technology)*, *17*(1), 01-05.

Roy, N., Basu, M., Das, S., Mandal, A., Dutt, D., & Dasgupta, S. (2015). Risk factors associated with default among tuberculosis patients in Darjeeling district of West Bengal, India. *Journal of family medicine and primary care*, *4*(3), 388

Rumende, C. M. (2018). Risk factors for multidrug-resistant tuberculosis. *Acta Medica Indonesiana*, *50*(1), 1.

Rustomjee, R.; Lienhardt, C.; Kanyok, T.; Davies, G.R.; Levin, J.; Mthiyane, T.; Reddy, C.; Sturm, A.W.; Sirgel, F.A.; Allen, J.; et al. A phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int. J. Tuberc. Lung Dis. 2008, 12, 128–138.

Samuels, J. P., Sood, A., Campbell, J. R., Ahmad Khan, F., & Johnston, J. C. (2018). Comorbidities and treatment outcomes in multidrug resistant tuberculosis: a systematic review and meta-analysis. *Scientific reports*, *8*(1), 4980.

Schwinghammer, T. L., Wells, B. G., Malone, P. M., Kolesar, J. M., & DiPiro, J. T. (2010). *Pharmacotherapy principles and practice*. McGraw-Hill.

Setiani, N. I., Fajarini, H., & Balfas, R. F. (2023). Pola Penggunaan Obat Tuberkulosis Resisten Obat pada Pasien Rawat Inap di Rumah Sakit Umum Daerah Brebes. *MOTEKAR: Jurnal Multidisiplin Teknologi dan Arsitektur*, *1*(2), 108-115.

Seyoum, B., Demissie, M., Worku, A., Bekele, S., & Aseffa, A. (2014). Prevalence and drug resistance patterns of Mycobacterium tuberculosis among new smear positive pulmonary tuberculosis patients in eastern Ethiopia. *Tuberculosis research and treatment*, *2014*.

Sinha, P., Jacobson, K. R., Horsburgh Jr, C. R., & Acuña-Villaorduña, C. (2023, April). At Long Last: Short, All-Oral Regimens for Multidrug-Resistant Tuberculosis in the United States. In Open Forum Infectious Diseases (Vol. 10, No. 4, p. ofad177). US: Oxford University Press.

Soedarsono, S., Mertaniasih, N. M., & Sulistyowati, T. (2020). First line anti-tuberculosis drug resistance pattern in multidrug-resistant pulmonary tuberculosis patients correlate with acid fast bacilli microscopy grading. *Indones. J. Trop. Infect. Dis*, *8*, 83.

Sugiyono. (2016). Metode Penelitian Kuantitatif Kualitataif dan Kombinasi (Mixed Methods). Bandung: Alfabeta.

Sutriyawan, A., Nofianti, N., & Halim, R. (2022). Faktor Yang Berhubungan dengan Kejadian Tuberkulosis Paru. *Jurnal Ilmiah Kesehatan (JIKA)*, *4*(1), 98-105.

Trébucq, A., Decroo, T., Van Deun, A., Piubello, A., Chiang, C. Y., Koura, K. G., & Schwoebel, V. (2019). Short-course regimen for multidrug-resistant tuberculosis: a decade of evidence. Journal of clinical medicine, 9(1), 55.

Ulya, F., & Thabrany, H. (2019). Efektivitas Biaya Strategi DOTS Program Tuberkulosis antara Puskesmas dan Rumah Sakit Swasta Kota Depok. *Jurnal Ekonomi Kesehatan Indonesia*, *3*(1).

Untari, S. D., & Asmini, P. (2018). *Evaluasi Rasionalitas Penggunaan Obat Anti Tuberkulosis Pada Pasien Rawat Inap TB MDR (Tubercuosis Multi Drug Resistance) Dewasa Di RSUD Dr. Moewardi Tahun 2016* (Doctoral dissertation, Universitas Muhammadiyah Surakarta).

Van Deun, A., Salim, H., Kumar Das, A. P., Bastian, I., & Portaels, F. (2004). Results of a standardised regimen for multidrug-resistant tuberculosis in Bangladesh. The International Journal of Tuberculosis and Lung Disease, 8(5), 560-567.

Walsh, K. F., Vilbrun, S. C., Souroutzidis, A., Delva, S., Joissaint, G., Mathurin, L., ... & Koenig, S. P. (2019). Improved outcomes with high-dose isoniazid in multidrug-resistant tuberculosis treatment in Haiti. Clinical Infectious Diseases, 69(4), 717-719.

Wang, Q., Pang, Y., Jing, W., Liu, Y., Wang, N., Yin, H., ... & Chu, N. (2018). Clofazimine for treatment of extensively drug-resistant pulmonary tuberculosis in China. *Antimicrobial agents and chemotherapy*, *62*(4), 10-1128.

Wibowo, A., Burhan, E., & Putra, A. C. (2021). Pola Resistansi Kuman Tuberkulosis dan Regimen Pengobatan Pada Pasien Tuberkulosis Resisten Obat Di Rumah Sakit Pusat Rujukan Respirasi Nasional

Persahabatan Jakarta. *Jurnal Kedokteran Universitas Lampung*, *5*(1), 1-6.

Widyasrini, E. R., & Probandari, A. N. (2017). Factors Affecting the Success of Multi Drug Resistance (MDR-TB) Tuberculosis Treatment in Residential Surakarta. *Journal of Epidemiology and Public Health*, *2*(1), 45-57.

World Health Organization. (2006). *Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis*. World Health Organization.

World Health Organization. (2010). *Treatment of tuberculosis: guidelines*. World Health Organization.

World Health Organization. (2013). *Definitions and reporting framework for tuberculosis–2013 revision: updated December 2014 and January 2020*. World Health Organization.

Wu, X., Yang, J., Tan, G., Liu, H., Liu, Y., Guo, Y., ... & Yu, F. (2019). Drug resistance characteristics of Mycobacterium tuberculosis isolates from patients with tuberculosis to 12 antituberculous drugs in China. *Frontiers in Cellular and Infection Microbiology*, *9*, 345.

Yobeanto, N., & Setiawan, T. L. (2022). Pola Resistensi Kuman Mycobacterium Tuberculosis Terhadap Obat Anti Tuberkulosis Lini Pertama. *Jurnal Health Sains*, *3*(5), 653-659.

Zhang, Y. (2014). Persisters, persistent infections and the Yin–Yang model. *Emerging microbes & infections*, *3*(1), 1-10.

Zhang, Y., & Yew, W. W. (2015). Mechanisms of drug resistance in Mycobacterium tuberculosis: update 2015. *The International Journal of Tuberculosis and Lung Disease*, *19*(11), 1276-1289.